Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Riddell, S. R.
Right arrow Articles by Greenberg, P. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Riddell, S. R.
Right arrow Articles by Greenberg, P. D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (2000) 45, 35-43
© 2000 The British Society for Antimicrobial Chemotherapy

T-cell therapy of cytomegalovirus and human immunodeficiency virus infection

S. R. Riddell* and P. D. Greenberg

Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, WA 98109, USA

Acute and persistent virus infections are limited by the development and maintenance of host T-cell responses to viral antigens. Individuals with congenital or acquired immunodeficiencies are at risk of progressive and often life-threatening infection. Recent studies have provided insight into the nature of protective T-cell responses to viruses and advances in T-cell culture technology have made it possible to evaluate the adoptive transfer of T-cell clones of defined antigen specificity and function to restore deficient responses in immunocompromised hosts. The progress of these studies in cytomegalovirus and human immunodeficiency virus infection is the subject of this review.

* Correspondence address. D3-100, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, Seattle, WA 98109, USA. Tel: +1-206-667-5249; Fax: +1-206-667-7983; E-mail: sriddell{at}fhcrc.org


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 BloodHome page
S. Gottschalk, O. L. Edwards, U. Sili, M. H. Huls, T. Goltsova, A. R. Davis, H. E. Heslop, and C. M. Rooney
Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies
Blood, March 1, 2003; 101(5): 1905 - 1912.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.